Previous Article | Next Article ![]()
Infection and Immunity, January 2001, p. 607-612, Vol. 69, No. 1
Department of Microbiology, Hellenic Pasteur
Institute, Athens 115 21, Greece,1 and
Moredun Research Institute, International Research Centre,
Pentlands Science Park, Penicuik, Midlothian EH26 OPZ, United
Kingdom2
Received 2 August 2000/Returned for modification 18 September
2000/Accepted 12 October 2000
Protective monoclonal antibodies (MAbs) to the major outer membrane
protein (MOMP) of species of the family Chlamydiaceae, which is the primary vaccine candidate antigen, recognize nonlinear epitopes conferred by the oligomeric conformation of the molecule. Protective MAbs failed to recognize oligomeric MOMP of the variant strain LLG, which bears amino acid substitutions in variable segments (VSs) 1, 2, and 4, and competed with monomer-specific MAbs mapping to
these VSs in reference strain 577. The results suggest that multiple
sites located in the three VSs contribute to the epitope of protective MAbs.
Chlamydophila abortus,
also known as Chlamydia psittaci serotype 1, is an important
pathogen of ruminants causing abortion late in gestation. The organism
can also be transmitted to humans, and pregnant women coming in contact
with the bacterium are also at risk of abortion (3).
Antibiotic treatment as a prophylactic measure is commonly used in some
countries. Other countries practice vaccination using commercially
available vaccines consisting of inactivated chlamydial elementary
bodies (EB) or a mutant strain (13). The development of an
alternative subunit vaccine that is cheap to produce, safe, and
effective is being sought both to prevent chlamydial abortions and to
diminish the spread and the risk of zoonosis. Currently the best
subunit vaccine candidate antigen is the 40-kDa major outer membrane
protein (MOMP). The MOMP is the most prevalent protein on the surface
of the EB (60% of outer membrane protein content) and constituted the
major antigen of a subcellular vaccine that conferred protection in
pregnant ewes (15). Sequence comparisons of the MOMPs from
several chlamydial species indicated the existence of four variable
sequences (VS1 to -4) flanked by five domains of conserved sequences
(10). In Chlamydia trachomatis, epitopes
located within the VS regions that had species, subspecies, and serovar
specificity were protective (20). In contrast to C. trachomatis infections, immunity to C. abortus
infection has been shown to be conferred by a 110-kDa oligomeric,
probably trimeric (7, 11, 18), form of the MOMP.
Monoclonal antibodies (MAbs) A11 and F3 that neutralized chlamydial
infectivity in vitro and protected pregnant mice from abortion after
passive transfer reacted only with the oligomer (1, 4, 7,
11). The epitopes that are recognized by these neutralizing MAbs
are unknown as yet.
We have previously reported the existence of naturally occurring
variant isolates of C. abortus in Greece. Strains LLG and POS were not recognized by several MAbs, including the anti-MOMP MAb
188 (17). Furthermore, we observed that the protective
MAbs A11 and F3 failed to react with inclusions of the two variant strains. Sequencing of variant antigens from escape mutants is a useful
approach to obtain important information concerning epitopes that
inhibit infectivity. In this report we have determined the amino acid
changes in the MOMP variant by DNA sequencing and defined the
localization of protective epitopes against C. abortus.
Strains LLG and POS were isolated in Greece from the lungs of aborted
caprine and ovine fetuses (17). Strain 577 was from the
American Type Culture Collection (Rockville, Md.). C. abortus isolates were grown and purified as described previously
(11, 17). Genomic DNA of strain LLG was obtained as
described by McClenaghan et al. (12), and the MOMP gene
(omp1) was amplified using the Expand Long Template PCR
system (Roche Molecular Biochemicals, Lewes, East Sussex, United
Kingdom) and primers flanking the MOMP coding region (forward primer,
5'-CAGGAYATCTTGTCTGGCTTTAA-3'; reverse primer,
5'-GGGCGAATTCTTATGCGAATGGAT-3'). The 1.4-kb PCR product was
ligated into T-vector pGEM-T (Promega, Southampton, United Kingdom) and
used to transform, by heat shock, Epicurian Coli XL-1 Blue
ultracompetent cells (Stratagene, La Jolla, Calif.). Recombinant
plasmid DNA was purified using a QIAprep Spin Plasmid Miniprep kit
(Qiagen Ltd., Crawley, United Kingdom) and sequenced on an ABI 377 automated DNA sequencer (Advanced Biotechnology Centre, Charing Cross
Hospital, London, United Kingdom). The characterization of the
antimonomer-specific MAbs 188 and 4/11 has been previously reported
(11, 14, 17). MAb 202, a genus-specific immunoglobulin G2a, was raised against a Greek abortion strain and was further characterized in this study. The properties of oligomer-specific MAbs
A11 and F3 have been described elsewhere (1, 4, 11). MAb
1B8, a serotype 1-specific immunoglobulin G2b, was raised against
abortion strain S26/3 and was provided by H. Kennedy (Queens University, Belfast, United Kingdom). The specificity of the novel MAbs
202 and 1B8 was tested using an immunoperoxidase assay on chlamydial
inclusions as described previously (17). Further characterization of the MAbs included Western blotting, peptide scanning, and neutralization, competition, and blocking assays. Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
have been described in detail elsewhere (17), as have the
synthesis of decapeptides spanning the four VSs of the MOMP and the
mapping of epitopes (14). The neutralization assays were
performed as previously recommended (5), in hamster kidney
cells (HaK, ATCC no. CCL15) by using purified MAbs and by following a
complement-assisted protocol (2). Inclusions were stained
in an immunoperoxidase assay with a genus-specific MAb and counted
using an inverted microscope at 200× magnification (Zeiss Axiovert).
Neutralization was considered efficient when the infectivity was
reduced by 50%. The blocking assay was initially developed for the
measurement of anti-MOMP antibodies in sera, and the technique has been
described in detail elsewhere (14). For the competition
assay, the competitor antibody was purified using a protein A-agarose
column (Pharmacia, Uppsala, Sweden) and biotinylated with biotin
succinimide as described previously (16). The biotinylated
MAbs were first titrated on enzyme-linked immunosorbent assay plates
coated with periodate-treated EB to determine the saturation point.
Competition was assessed with serial dilutions of the biotinylated
competitor MAb and constant amounts of the unlabeled inhibitor MAb. In
the blocking assays the competition was between a constant amount of
the biotinylated competitor and serial dilutions of the nonlabeled inhibitor.
Reactivity of the MOMP-specific MAbs.
The reactivity of MAbs
against the MOMP monomer and oligomer is summarized in Table
1. The monomer-specific MAbs 188, 4/11, and 202 did not cause an efficient neutralization of strain 577 in the
presence of complement (reduction of infectivity by 30, 30, and 45%,
respectively), whereas the oligomer-specific MAb 1B8 reduced the
infectivity by 85%. The neutralizing capabilities of A11 and F3 were
similar to those originally reported (1), with 80 and
62%, respectively. The antioligomer MAbs did not react with any of 38 previously (14) synthesized overlapping peptides spanning
the four variable segments of the MOMP. This result was in accordance
with the previous findings concerning the conformational nature of the
corresponding epitopes. MAb 202 mapped to the hydrophobic domain in
VS4, which is conserved among species of the family Chlamydiaceae (Table 1).
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.607-612.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Protective Epitopes by Sequencing
of the Major Outer Membrane Protein Gene of a Variant Strain of
Chlamydia psittaci Serotype 1 (Chlamydophila
abortus)
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Reactivity of MOMP-specific MAbs
Failure of the neutralizing MAbs to react with the MOMP oligomer of
the variant strain.
To determine whether any of the neutralizing
MAbs would recognize the MOMP oligomer of the variant strain, we
performed Western blotting with either unheated or boiled EB of the
reference strain 577 and the variant strain LLG (Fig.
1). The results with strain 577 show that
the neutralizing MAbs A11 (lane 4) and 1B8 (lane 6) recognized two
major regions above the marker at 94 kDa, corresponding to the 110-kDa
MOMP oligomer previously identified with A11 (11). MAb F3
had an identical pattern to A11 (data not shown). The corresponding regions of the MOMP oligomer of the variant strain LLG were not recognized by the neutralizing MAbs (lanes 3 and 5), in agreement with
the results obtained upon immunoperoxidase staining of inclusions (Table 1). The anti-VS2 MAb 4/11 reacted with the MOMP monomers of both
strains 577 and LLG (lanes 7 and 8, respectively). MAb 4/11 also weakly
recognized the MOMP oligomers of both the reference and the variant
strains (lanes 1 and 2) and so has mixed monomer and oligomer
specificity, as previously indicated (11).
|
Sequence variations in the omp1 gene of strain LLG. To determine the sequence difference(s) between abortifacient strains LLG and 577, the entire omp1 of strain LLG was sequenced and compared with published sequence data (accession number M73036) (10). The comparison showed seven nucleotide changes at positions 286, 493, 612, 856, 966, 976, and 989 in the coding sequence. The variations at nucleotide (nt) 286 and 493 were within VS1 and VS2 and resulted in amino acid changes at positions 96 (Asn to Asp) and 165 (Ile to Val). The substitutions at nt 612 and 966 were silent. The variations at nt 856, 976, and 989 resulted in three amino acid replacements, one before and two within the VS4 domain. 286Ser was replaced by Gly, 326Ala was replaced by Thr, and 330Ser was replaced by Asn.
Topology prediction of the variant positions in the MOMP.
To
locate the positions of the substituted amino acids in the MOMP
molecule, we used a neural network (NN), which is accessible online
(http://strucbio.biologie.uni-konstanz.de), to predict the topology of
outer membrane (OM) proteins based on their sequence. The NN predicts
the z coordinate of C
atoms in a coordinate frame with
the OM in the xy plane. Low z values (below 0.4)
indicate periplasmic turns, medium z values indicate
transmembrane
-strands, and high z values (>0.6)
indicate extracellular loops (8). The output of the NN for
the MOMP of reference is shown in Fig. 2.
The five amino acid substitutions in LLG-MOMP are indicated (Fig. 2).
The mutations in VS1 and VS2 were predicted to be located in
extracellular loops, which correlates well with their localization within a surface-exposed variable segment. The z values of
the two conservative replacements in VS4 were <0.6. The topology
prediction of the nonconservative exchange of 286Ser to Gly was
periplasmic. This is in good agreement with the fact that a Gly residue
is conserved in most MOMP alleles, with the exception of the reference abortion strains 577 (10) and S26/3 (9).
286Gly is replaced by Ser in these two alleles.
|
Competition assays between antimonomer and antioligomer MAbs. The replacement of 96Asn by Asp in VS1 was located within the epitope of MAb 188 and probably affected the binding of this MAb to strain LLG (Table 1) (17). This suggestion was reconfirmed by using synthetic peptides. Two decapeptides corresponding to the epitope of MAb 188, but with the substitution found in strain LLG, were synthesized and tested. Binding of MAb 188 to decapeptide 89PTGTAAANYK98 decreased by 20%, and binding to peptide 91GTAAANYKPT100 decreased by 75%, both after substitution of 96Asn by Asp.
The DNA sequencing results also implied that amino acids 96 in VS1, 165 in VS2, and 326 and 330 in VS4 were directly or indirectly involved in the epitope(s) of the neutralizing MAbs A11, F3, and 1B8. While conclusions relevant to linear epitopes can be reconfirmed by the use of synthetic peptides, those concerning conformational epitopes are more difficult to support by direct evidence. We used the competition approach. Antimonomer MAbs 188, 4/11, and 202 (against VS1, VS2, and VS4, respectively) (Table 1) were labeled with biotin and were allowed to compete with the antioligomer, neutralizing MAbs F3, A11, and 1B8 for binding to strain 577 EB-coated enzyme-linked immunosorbent assay plates. As shown in the double-reciprocal plots in Fig. 3A and B, the binding of MAbs 188 and 4/11 to EB was inhibited in a competitive manner by the presence of MAbs 1B8, A11, and F3. Interestingly, MAb 188 inhibited the binding of MAb 4/11 and vice versa (data not shown), indicating that VS1 and VS2 are in close proximity. The data obtained with the anti-VS4 MAb 202 differentiated the reactivity of the neutralizing MAbs A11, F3, and 1B8. The results (Fig. 3C) showed that MAbs A11 and F3 at 10 µg/ml competitively inhibited the binding of MAb 202, whereas MAb 1B8 stimulated the binding of MAb 202 at the same concentration and noncompetitively inhibited it at 0.01 µg/ml. The presence of the nonprotective MAb 188 did not affect the binding of MAb 202 (Fig. 3C). Blocking assays were also performed with a fixed concentration of labeled MAb 188 that was determined by titration to 75% of maximum binding. The concentrations of the blocking antibody that reduced the binding of the labeled MAb by 50% were determined to be 7.5, 9.0, 0.1, and 1.5 µg/ml for MAbs A11, F3, 1B8, and 4/11, respectively. Correspondingly, the binding of labeled MAb 4/11 was reduced by 50% with blocking antibody concentrations of 5.4, 7.5, 0.05, and 10 µg/ml for MAbs A11, F3, 1B8, and 188, respectively. The results suggest that multiple sites located in the three VSs (VS1, VS2, and VS4) are involved in the formation of the epitopes of the neutralizing anti-MOMP MAbs.
|
Nucleotide sequence accession number. The complete coding sequence of the LLG strain MOMP has been deposited in the GenBank DNA database and assigned accession number AF272945.
| |
ACKNOWLEDGMENTS |
|---|
We thank A. A. Andersen (Agricultural Research Service, Ames, Iowa) for the gift of MAbs A11 and F3 and H. Kennedy (Queens University, Belfast, United Kingdom) for MAb 1B8.
This work was supported by EU contract CT93-0957 (AIR-3).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Hellenic Pasteur Institute, 127 Vassilissis Sofias Ave., 115 21 Athens, Greece. Phone and fax: (301) 64 78 873. E-mail: evretou{at}netor.gr.
Editor: D. L. Burns
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Andersen, A. A., and R. A. Van Deusen.
1988.
Production and partial characterization of monoclonal antibodies to four Chlamydia psittaci isolates.
Infect. Immun.
56:2075-2079 |
| 2. | Ando, S., I. Takashima, and N. Hashimoto. 1993. Neutralization of Chlamydia psittaci with monoclonal antibodies. Microbiol. Immunol. 37:753-758[Medline]. |
| 3. | Buxton, D. 1986. Potential danger to pregnant women of Chlamydia psittaci from sheep. Vet. Rec. 118:510-511[Medline]. |
| 4. | Buzoni-Gatel, D., F. Bernard, A. A. Andersen, and A. Rodolakis. 1990. Protective effect of polyclonal and monoclonal antibodies against abortion in mice infected by Chlamydia psittaci. Vaccine 8:342-346[CrossRef][Medline]. |
| 5. | Byrne, G. I., R. S. Stephens, G. Ada, H. D. Caldwell, H. Su, R. P. Morrison, B. Van der Pol, P. M. Bavoil, L. Bobo, S. Everson, Y. Ho, R.-C. Hsia, K. Kennedy, C.-C. Kuo, P. C. Montgomery, E. Peterson, A. Swanson, C. Whitaker, J. Whittum-Hudson, C. L. Yang, Y.-X. Zhang, and G. M. Zhong. 1993. Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. J. Infect. Dis. 168:415-420[Medline]. |
| 6. | Cowan, S. W., T. Schirmer, G. Rummel, M. Steiert, R. Ghosh, R. A. Pauptit, J. N. Jansonius, and J. P. Rosenbusch. 1992. Crystal structures explain functional properties of two E. coli porins. Nature 358:727-733[CrossRef][Medline]. |
| 7. | De Sa, C., A. Souriau, F. Bernard, J. Salinas, and A. Rodolakis. 1995. An oligomer of the major outer membrane protein of Chlamydia psittaci is recognized by monoclonal antibodies which protect mice from abortion. Infect. Immun. 63:4912-4916[Abstract]. |
| 8. | Dieterichs, K., J. Freigang, S. Umhau, and J. Breed. 1998. Prediction by a neural network of outer membrane beta-strand protein topology. Protein Sci. 7:2413-2420[Medline]. |
| 9. | Herring, A. J., T. W. Tan, S. Baxter, N. F. Inglis, and S. Dunbar. 1989. Sequence analysis of the major outer membrane protein gene of an ovine abortion strain of Chlamydia psittaci. FEMS Microbiol. Lett. 65:153-158[CrossRef]. |
| 10. |
Kaltenboeck, B.,
K. G. Kousoulas, and J. Storz.
1993.
Structures of and allelic diversity and relationships among the major outer membrane protein (ompA) genes of the four chlamydial species.
J. Bacteriol.
175:487-502 |
| 11. | McCafferty, M. C., A. J. Herring, A. A. Andersen, and G. E. Jones. 1995. Electrophoretic analysis of the major outer membrane protein of Chlamydia psittaci reveals multimers which are recognized by protective monoclonal antibodies. Infect. Immun. 63:2387-2389[Abstract]. |
| 12. |
McClenaghan, M.,
A. J. Herring, and L. D. Aitken.
1984.
Comparison of Chlamydia psittaci isolates by DNA restriction endonuclease analysis.
Infect. Immun.
45:384-389 |
| 13. | Rodolakis, A., J. Salinas, and J. R. Papp. 1998. Recent advances on ovine chlamydial abortion. Vet. Res. 29:275-288[Medline]. |
| 14. | Salti-Montesanto, V., E. Tsoli, P. Papavassiliou, E. Psarrou, B. Markey, G. E. Jones, and E. Vretou. 1997. Diagnosis of ovine enzootic abortion, using a competitive ELISA based on monoclonal antibodies against variable segments 1 and 2 of the major outer membrane protein of Chlamydia psittaci serotype 1. Am. J. Vet. Res. 58:228-235[Medline]. |
| 15. |
Tan, T. W.,
A. J. Herring,
I. E. Anderson, and G. E. Jones.
1990.
Protection of sheep against Chlamydia psittaci infection with a subcellular vaccine containing the major outer membrane protein.
Infect. Immun.
58:3101-3108 |
| 16. |
Vretou, E.,
P. C. Goswami, and S. K. Bose.
1989.
Adherence of multiple serovars of Chlamydia trachomatis is mediated by thermolabile protein(s) to a common receptor on HeLa and McCoy cells.
J. Gen. Microbiol.
135:3229-3237 |
| 17. | Vretou, E., E. Loutrari, L. Mariani, K. Costelidou, P. Eliades, G. Conidou, S. Karamanou, O. Mangana, V. Siarkou, and O. Papadopoulos. 1996. Diversity among abortion strains of Chlamydia psittaci demonstrated by inclusion morphology, polypeptide profiles and monoclonal antibodies. Vet. Microbiol. 51:275-289[CrossRef][Medline]. |
| 18. |
Wyllie, S.,
R. H. Ashley,
D. Longbottom, and A. J. Herring.
1998.
The major outer membrane protein of Chlamydia psittaci functions as a porin-like ion channel.
Infect. Immun.
66:5202-5207 |
| 19. | Wyllie, S., D. Longbottom, A. J. Herring, and R. H. Ashley. 1999. Single channel analysis of recombinant major outer membrane protein porins from Chlamydia psittaci and Chlamydia pneumoniae. FEBS Lett. 445:192-196[CrossRef][Medline]. |
| 20. | Zhang, Y.-X., S. Stewart, T. Joseph, H. R. Taylor, and H. D. Caldwell. 1987. Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis. J. Immunol. 138:575-581[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»